Victory for Trump: U.S. Drug Prices Match Europe

In a groundbreaking announcement poised to reshape the pharmaceutical landscape, Bristol Myers Squibb (BMS) has declared that its revolutionary schizophrenia drug, Cobenfy, will launch in the UK at the same price as in the U.S. — a move that symbolizes a significant victory for President Donald Trump's relentless crusade against high American drug costs. This unprecedented decision breaks new ground in aligning international pricing, challenging the longstanding practice of "foreign free-riding," and pushing back against an industry historically shielded from scrutiny. BMS Chief Commercialization Officer Adam Lenkowsky underscored the company's commitment to ensuring that other countries pay their fair share for innovative therapies, highlighting the ethical imperative outlined by Trump that has resonated with countless American patients burdened by skyrocketing prescription costs. While the UK is under pressure to recognize the value of this transformational medication, Lenkowsky made it clear that BMS is prepared to walk away from the market rather than compromise its principles, a bold stance that echoes Trump’s assertion that no American should be forced to subsidize the healthcare of other nations. As Trump continues to champion policies aimed at leveling the playing field in global healthcare pricing, this latest development signals a turning tide that could finally bring relief to American consumers tired of